EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)
JH Cho, SH Lim, HJ An, KH Kim, KU Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
J Biton, A Mansuet-Lupo, N Pécuchet, M Alifano… - Clinical Cancer …, 2018 - AACR
Purpose: By unlocking antitumor immunity, antibodies targeting programmed cell death 1
(PD-1) exhibit impressive clinical results in non–small cell lung cancer, underlining the …
(PD-1) exhibit impressive clinical results in non–small cell lung cancer, underlining the …
[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases
JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Y Kobayashi, T Mitsudomi - Cancer science, 2016 - Wiley Online Library
Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …
Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy
T Nagano, M Tachihara, Y Nishimura - Cells, 2018 - mdpi.com
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …
Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine
kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly …
kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly …
Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung …
PC Hsu, DM Jablons, CT Yang, L You - International journal of molecular …, 2019 - mdpi.com
The epidermal growth factor receptor (EGFR) pathway is a well-studied oncogenic pathway
in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15 …
in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15 …